MedTrace Logo

Tisagenlecleucel In Primary CNS Lymphoma

NCT04134117 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-01-09

No results posted yet for this study

Summary

In this study, is researching the safety of tisagenlecleucel in participants with primary central nervous system lymphoma. .

-The name of the study intervention is tisagenlecleucel.

Conditions

  • Primary CNS Lymphoma
  • Refractory Primary CNS Lymphoma
  • Relapsed Primary CNS Lymphoma

Interventions

BIOLOGICAL

Tisagenlecleucel

One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Matthew J. Frigault, M.D.

    lead OTHER

Principal Investigators

  • Matthew J. Frigault, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2022-04-14
Completion
2022-04-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04134117 on ClinicalTrials.gov